By Miriam Hill
Inquirer Staff Writer
Barton’s attorney, Zoe Littlepage, argued that the public’s right to know outweighed those concerns and that Wyeth had failed to prove damage, not just speculate that it could occur. Littlepage also said she feared that Wyeth would use the tactic to delay repeatedly as 9,000 cases involving Pfizer/Wyeth menopause drugs make their way through the courts.
Mazer Moss, who oversees the Common Pleas Court’s Complex Litigation arm, said that while she respected the public’s right to know, she had to balance that against the “interest in a fair trial” in the Kendall case.
After deliberations yesterday, two jurors said they would not discuss the amount but they did say they thought the decision should have been made public immediately. Jurors Joanne Gwardyak and Jennifer Young said they saw the decision to seal the verdict as an attempt to hide negative news about Wyeth. They said they thought the Kendall jury would be able to be fair even if the verdict was made public.
“Every case is different,” Gwardyak said.
A Pfizer spokesman said the company did not agree with the outcome of the case.
“We are disappointed with the jury’s verdict and will weigh all of our legal options regarding our next steps in this case,” Pfizer said in a statement.
Barton was diagnosed with cancer in 2002, five years after she began taking Prempro to treat menopausal symptoms. McDavid had argued that Barton had breast cancer before she began taking Prempro.
More than six million women have taken hormone-replacement medicines to treat menopause symptoms such as hot flashes, night sweats, and mood swings.
Prempro sales fell significantly after a U.S. study in 2002 linked the therapy to breast cancer and cardiovascular risks.
The company has now lost five of eight trials over its hormone-replacement drugs since cases began reaching juries in 2006.
Some of the verdicts were set aside, and others are on appeal, according to Bloomberg News.
Pfizer is based in New York, but it employs about 4,500 people in Collegeville and Great Valley. The Great Valley facility is expected to close next year as the result of the merger. It is not clear how many jobs will remain in Collegeville. The combined company expects to cut about 20,000 out of 130,000 jobs companywide.
Contact staff writer Miriam Hill at 215-854-5520 or email@example.com.